Latest Breaking News On - Efficacy results - Page 2 : vimarsana.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

MALVERN, Pa., May 02, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun.

Tarun upadhyayOcugen incHead of communicationsRetina world congressExchange commissionPanel sessionHead of research developmentChief scientific officerGene therapyMarriott harbor beachEfficacy resultsRetinitis pigmentosaPrivate securities litigation reform act

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights

01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib .

Jack baileyJohnw umsteadDrug administration onPepper bio incInvestor relations corporate communicationsTherapeutics incExchange commissionDrug administrationThat final analysisEvaluating overall survivalMetastatic triple negative breast cancerLate second quarterRunway expectedThird quarterHost webcastConference call

enVVeno Medical Corporation: Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical s VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

enVVeno Medical Corporation: Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical s VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Eastern virginia medical schoolUnited statesUnited kingdomCity ofCharing crossRobert bermanJenene thomasDennis riedlDavid dexterCharing cross international symposiumExchange commissionVveno medical corporation the companyVveno medical corporationRevised venous clinical severity scoreImprovement per patientPatients showing clinical meaningful benefit

enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve

enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomEastern virginia medical schoolUnited statesCharing crossDavid dexterJenene thomasRobert bermanVveno medical corporationVveno medical corporation the companyExchange commissionCharing cross international symposiumRevised venous clinical severity scoreImprovement per patientPatients showing clinical meaningful benefitWeighted average